- Home
- FIVE vs CYTK Comparison
FIVE vs CYTK Comparison
Compare FIVE & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- CYTK
- Stock Information
- Founded
- FIVE 2002
- CYTK 1997
- Country
- FIVE United States
- CYTK United States
- Employees
- FIVE N/A
- CYTK N/A
- Industry
- FIVE Department/Specialty Retail Stores
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- CYTK Health Care
- Exchange
- FIVE Nasdaq
- CYTK Nasdaq
- Market Cap
- FIVE 5.2B
- CYTK 5.0B
- IPO Year
- FIVE 2012
- CYTK 2004
- Fundamental
- Price
- FIVE $85.92
- CYTK $50.26
- Analyst Decision
- FIVE Buy
- CYTK Strong Buy
- Analyst Count
- FIVE 21
- CYTK 17
- Target Price
- FIVE $126.21
- CYTK $82.00
- AVG Volume (30 Days)
- FIVE 1.3M
- CYTK 1.9M
- Earning Date
- FIVE 03-19-2025
- CYTK 02-27-2025
- Dividend Yield
- FIVE N/A
- CYTK N/A
- EPS Growth
- FIVE 0.08
- CYTK N/A
- EPS
- FIVE 4.85
- CYTK N/A
- Revenue
- FIVE $3,823,378,000.00
- CYTK $3,219,000.00
- Revenue This Year
- FIVE $11.23
- CYTK N/A
- Revenue Next Year
- FIVE $10.33
- CYTK $754.18
- P/E Ratio
- FIVE $17.70
- CYTK N/A
- Revenue Growth
- FIVE 14.32
- CYTK N/A
- 52 Week Low
- FIVE $64.87
- CYTK $40.53
- 52 Week High
- FIVE $212.01
- CYTK $81.36
- Technical
- Relative Strength Index (RSI)
- FIVE 38.73
- CYTK 58.40
- Support Level
- FIVE $85.82
- CYTK $45.05
- Resistance Level
- FIVE $94.91
- CYTK $48.30
- Average True Range (ATR)
- FIVE 3.57
- CYTK 2.80
- MACD
- FIVE -0.15
- CYTK 0.61
- Stochastic Oscillator
- FIVE 2.67
- CYTK 86.80
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.